Your search matched 64 results
Representatives from small and big pharma, and those fighting both rare diseases and more prevalent ones, came together in San Diego recently for WIB-Southern California: The Growing Importance of Patient Advocacy in BioPharma.
And, turns out, it’s what patient advocacy groups want from pharma, too.
How Patient Advocacy Connectivity Fuels Launch Success | Perspectives
Keri McDonough, our communications and advocacy relations strategist, lays out our top 10 recommendations for meaningful patient advocacy group engagement on the runway to launch and beyond.
As anticipated, on June 6, 2018, Senator Claire McCaskill (D-Mo.) introduced the Patient Advocacy Transparency Act.
Keri McDonough, one of our patient advocacy specialists, provides ten recommendations on how to meaningfully engage with patient advocacy groups throughout the lifecycle of a product.
SHARING THE MISSION TO CONQUER RARE DISEASES | Perspectives
At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.
Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.
The Syneos Health Podcast: Advocacy Archetypes | Perspectives
Patient advocacy has evolved over time, and with it, patient advocate archetypes have emerged.
In this guest blog, Keri Mcdonough, Lead, Advocacy and Patient Relations at Syneos Health Communications shares her insight on how to assemble a patient advisory board that accurately and effectively represents the patient voice.
Opening a New Era in Rare Disease Medicines | In The Media
Jeanine O'Kane and Marie Emms, senior executives at Syneos Health, address rare disease pricing and the ties between manufacturers, payers and patient advocacy groups.
Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".
Keri McDonough, Patient Advocacy Lead at Syneos Health Communications, was featured in MedCity News discussing how CROs can highlight the practical and socioeconomic barriers to greater trial diversity.
Learn about why it's still important to consider a human approach in healthcare communications from Jeanine O'Kane, President, Public Relations Group at inVentiv Health Communications.
Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.
Live from EFP ‘18: This afternoon, a panel of 5 patients, advocates and pharma-patient connectors engaged in a discussion titled, “Where is the trust?
Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.
Mark Baglin, Vice President of Global Marketing at Alnylam Pharmaceuticals, works in ultra ultra rare diseases, like Hereditary ATTR Amyloidosis.
Betting Big on Cancer.com | Blog
This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.
Clinical Educators: Positive Impact on Patient Experiences | Perspectives
Clinical educators can help empower the patient to make their own informed healthcare choices.
Chandler Chicco Agency | Agency
Global PR agency pioneering health communications programs that engage key stakeholders throughout the product lifecycle.
Demands for real world evidence and patient-reported outcomes are changing how and when new drugs file for approval.
This summer, students in California Institute for Regenerative Medicine’s Bridges to Stem Cell Research and Therapy program at California State University (CSU) San Marcos had new lab partners: families impacted by rare diseases.
AN ADVOCACY RX FOR PROGRESS IN MENTAL HEALTH | Perspectives
As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis.
TWTW team spent this weekend doing some spring cleaning in the hopes that it would bring us East Coasters some, well, spring…Fingers crossed that a little wishful thinking and the removal of some pretty major dust bunnies will get the warm weather vibes coming our way.
Reputation & Risk Management | Shared-accelerator
Reputation & Risk Management
These patients represent the foundation of getting new and better treatments FDA-approved and in the hands of the patients that need them.
Fake News Invades Healthcare | Blog
The “fake news” phenomenon is more than just a problem for politics.
Recently, the FDA issued Collecting Comprehensive and Representative Input, the first of four patient-focused drug development (PFDD) guidance documents.
The Rep Evolution | Blog
Recently, one of our clients asked the GSW innovation team if there was some way to flip the typical rep ad board meeting and turn it into something more engaging… more productive… more (saw this one coming) innovative.
Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.